These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31677335)

  • 1. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
    Zhang Y; Du H; Li Y; Yuan Y; Chen B; Sun S
    Cancer Sci; 2020 Feb; 111(2):637-646. PubMed ID: 31677335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
    Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
    Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
    He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
    Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
    Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a.
    Du H; Li Y; Sun R; Yuan Y; Sun S; Zhang Y
    Thorac Cancer; 2020 Sep; 11(9):2473-2482. PubMed ID: 32648688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and significance of IKBKB in pulmonary adenocarcinoma A549 cells and its cisplatin-resistant variant A549/DDP].
    Qi K; Li Y; Li X; Zhang F; Shao Y; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):363-8. PubMed ID: 24854552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
    Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
    Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inverse interaction between
    Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
    Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
    Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
    Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
    Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
    Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of galectin-1 gene silencing on resistance to cisplatin in human lung adenocarcinoma A549 cells.
    Zhang L; Liu X; Tang Z; Li X; Wang G
    Biomed Pharmacother; 2016 Oct; 83():265-270. PubMed ID: 27392028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms.
    Ye MX; Zhao YL; Li Y; Miao Q; Li ZK; Ren XL; Song LQ; Yin H; Zhang J
    Phytomedicine; 2012 Jun; 19(8-9):779-87. PubMed ID: 22483553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway.
    Qi K; Li Y; Li X; Lei X; Wang B; Zhang L; Chu X
    Anticancer Drugs; 2016 Nov; 27(10):970-8. PubMed ID: 27537399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.
    Danni X; Jiangzheng Z; Huamao S; Yinglian P; Changcheng Y; Yanda L
    Bioengineered; 2021 Dec; 12(1):7335-7347. PubMed ID: 34612768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.